Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Our DNA
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
    • Our Charity Fund
  • Support
    • Our Value Creation
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera

ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera

ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services

 March

 27, 

2023

Majority owner ARCHIMED and partners CAPZA and Siparex finance add-on acquisition by European safety testing company – and French market leader – CARSO

 March

 16, 

2023

ARCHIMED buys WiQo, a pioneer in the field of aesthetic medicine

 March

 9, 

2023

ARCHIMED invests in PlasmidFactory, a German gene and cell therapy specialist

 October

 7, 

2022

ARCHIMED Impact Report 2021 – Investing for Better Healthcare: a Global Challenge

 October

 4, 

2022

ARCHIMED acquires Nasdaq-listed Natus Medical Incorporated in $1.1 billion take-private deal

 July

 21, 

2022

< 1 2 3 4 … 13 >
368
  • ARCHIMED © 2023
  • Our Eco Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
    Go top

    Back to top